Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
111.1 USD -2.96% Intraday chart for Illumina, Inc. +0.49% -20.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Daiwa Securities Adjusts Price Target on Illumina to $120 From $133 MT
Transcript : Illumina, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
Transcript : Illumina, Inc. - Analyst/Investor Day
Illumina Files Registration Statement for Planned GRAIL Divestiture MT
Bernstein Adjusts Illumina's Price Target to $130 From $129 MT
TD Cowen Adjusts Illumina's Price Target to $140 From $150 MT
Baird Raises Price Target on Illumina to $128 From $125 MT
Evercore ISI Adjusts Price Target on Illumina to $195 From $200 MT
Leerink Adjusts Price Target on Illumina to $150 From $155 MT
Illumina reaffirms annual revenue forecast over continued sluggish demand RE
Illumina Q1 Non-GAAP Earnings Increase, Revenue Decreases -- Shares Down After Hours MT
Transcript : Illumina, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (ILMN) ILLUMINA Posts Q1 EPS $0.09, vs. Street Est of $0.10 MT
Earnings Flash (ILMN) ILLUMINA Posts Q1 Revenue $1.08B, vs. Street Est of $1.05B MT
Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024 CI
Illumina, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Bernstein Adjusts Price Target on Illumina to $129 From $150 MT
Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept MT
HSBC Adjusts Illumina Price Target to $130 From $140 MT
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca Our Logo
Baptista Research Downgrades Illumina to Hold From Buy, Adjusts PT to $149.60 From $145 MT
The European Commission Approves Illumina's Plan to Divest Grail CI
Leerink Partners Adjusts Illumina's Price Target to $155 From $170 MT
Illumina Secures European Commission's Approval for Grail Divestment MT
European Commission Clears Illumina's Proposed Sale of Cancer Test Maker Grail MT
Chart Illumina, Inc.
More charts
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
111.1 USD
Average target price
155.5 USD
Spread / Average Target
+40.01%
Consensus
  1. Stock Market
  2. Equities
  3. ILMN Stock
  4. News Illumina, Inc.
  5. Sector Update: Healthcare Stocks Mostly Higher Late Thursday
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW